Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
about
Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation.Rapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion.A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trialEffect of Spironolactone on Plasma Apelin-12 Levels in Patients with Chronic Systolic Heart FailureEfficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.Pathophysiology and clinical evaluation of acute heart failure.Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.Mineralocorticoid Receptor Antagonism in Acute Heart Failure.Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation.Lack of Diuretic Efficiency (but Not Low Diuresis) Early in An Acutely Decompensated Heart Failure Episode Is Associated with Increased 180-Day Mortality.Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy.Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure.Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
P2860
Q33856656-4A91CE28-0061-45A7-9C29-C5961FAA65B8Q35722993-98F1F917-90F8-4E19-9DED-4010E90578EBQ37098407-7C0F190B-4DAE-43D2-9AF8-41CDC6D1256CQ37240299-4153D2F0-44BD-45BA-8BE2-07CA5EAC8789Q37448653-B607DEAF-1179-49C0-9172-EB546EE43BF5Q38374127-2FDEE661-1B63-4F47-9F87-474DF79E6829Q38586834-9BF47042-86E6-41A7-946E-33173F96BFBFQ38927295-9BAF2F0D-41BE-4DBF-80DB-9E925B176356Q39024503-EE7C254E-3296-40D2-8CA1-890A6127A2A8Q39893116-4C50C89A-A038-47B4-92D0-83FC26D4F7C2Q39958637-A7064EF5-E6DD-48E6-AE8F-EEFD430787A6Q40459537-58CA8953-BE16-46A7-9E8B-6FF673C0B168Q40710330-DB1A1B02-304D-4856-B865-89292D8E48D2Q40936792-510F233A-C853-4CD6-A401-8FED1B308E2FQ47346771-759B2F52-4D26-42D9-9B72-613CFA122FEFQ47898606-6FA5B3BA-9C40-4888-A9B2-20D89617D36CQ49203906-5BB11974-E06E-47D0-AD42-FBA6077F8757Q50047461-8A85355D-FA4C-4DA3-87C4-C897CBB5C5EEQ51019622-CF6802E0-CF4C-439A-A03A-4ABD53EBEF25Q58796491-B063D4B2-F9E2-4D87-8554-3B8357DB92B0
P2860
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@en
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@nl
type
label
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@en
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@nl
prefLabel
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@en
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@nl
P2093
P2860
P50
P921
P356
P1476
Serum aldosterone is associate ...... alysis from the EVEREST trial.
@en
P2093
Angela Fought
EVEREST investigators
Marvin A Konstam
P2860
P304
P356
10.1093/EURJHF/HFT100
P50
P577
2013-06-19T00:00:00Z